Teradyne reported strong Q1 fiscal 2026 results with $1.28 billion revenue, up 87% year-over-year, driven by nearly 70% of sales from AI-related products. Non-GAAP EPS rose 318% to $2.56, and the company projects Q2 revenue up to $1.25 billion with EPS of $2.15. Institutional investors are heavily buying Teradyne shares, reflecting confidence in its growth and profitability, with sales growth at 13.3% and profit margin at 17.4%. This momentum and solid fundamentals suggest Teradyne could continue to perform well in the market.
The ARK Space Exploration & Innovation ETF (ARKX) has gained popularity as a diversified alternative for investors seeking space industry exposure without relying solely on the upcoming SpaceX IPO. With $893 million in assets and 35 holdings across l...
The global therapeutic apheresis market, valued at $3.84 billion in 2025, is projected to grow to $8.94 billion by 2035 at a 7.9% CAGR. Growth is fueled by rising chronic and autoimmune diseases, advances in automated apheresis technology, and expand...
